The W232R suppressor mutation promotes maturation of a truncation mutant lacking both nucleotide-binding domains and restores interdomain assembly and activity of P-glycoprotein processing mutants

Biochemistry

Volumn 50, Issue 5, 2011, Pages 672-685

  Loo, Tip W ^a   Bartlett, M Claire ^a   Clarke, David M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATP-BINDING CASSETTE; GENETIC MUTATIONS; HYDROGEN BOND INTERACTION; HYDROGEN BONDINGS; INTER-DOMAIN; INTRA-DOMAIN; INTRA-DOMAIN INTERACTIONS; NUCLEOTIDE-BINDING DOMAIN; P-GLYCOPROTEIN; TRANSMEMBRANE DOMAIN; TRUNCATION MUTANTS;

AMINO ACIDS; ARGININE; GLYCOPROTEINS; HYDROGEN; HYDROGEN BONDS; NUCLEOTIDES; RESTORATION;

GRID COMPUTING;

ABC TRANSPORTER; ARGININE; GLYCOPROTEIN P; MUTANT PROTEIN;

ANIMAL CELL; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SUPPRESSOR GENE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; CELL LINE; CRICETINAE; HUMANS; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; NUCLEOTIDES; P-GLYCOPROTEIN; PROTEIN BINDING; PROTEIN FOLDING; SUPPRESSION, GENETIC;

EID: 79952079093     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi1016809     Document Type: Article

References (99)

1. Holland, I. B., and Blight, M. A. (1999) ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J. Mol. Biol. 293, 381-399. (Pubitemid 29516178)
2. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman, M. M. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361-398. (Pubitemid 29222564)
3. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. (1987) Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U. S. A. 84, 7735-7738.
4. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P., Berns, A. J. M., and Borst, P. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502. (Pubitemid 24153990)
5. Lee, C. G., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I., and Dey, S. (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37, 3594-3601. (Pubitemid 28162914)
6. Chen, C. J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., and Roninson, I. B. (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47, 381-389. (Pubitemid 17210152)
7. Loo, T. W., and Clarke, D. M. (1995) Membrane topology of a cysteine-less mutant of human P-glycoprotein. J. Biol. Chem. 270, 843-848.
8. Loo, T. W., and Clarke, D. M. (1999) The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to MEDiate drug binding and trafficking to the cell surface. J. Biol. Chem. 274, 24759-24765.
9. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2002) The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing Walker A sequence. J. Biol. Chem. 277, 41303-41306. (Pubitemid 35257428)
10. Senior, A. E., and Gadsby, D. C. (1997) ATP hydrolysis cycles and mechanism in P-glycoprotein and CFTR. Semin. Cancer Biol. 8, 143-150. (Pubitemid 28041011)
11. Loo, T. W., and Clarke, D. M. (1995) Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. J. Biol. Chem. 270, 22957-22961.
12. Urbatsch, I. L., Sankaran, B., Bhagat, S., and Senior, A. E. (1995) Both P-glycoprotein nucleotide-binding sites are catalytically active. J. Biol. Chem. 270, 26956-26961.
13. Loo, T. W., and Clarke, D. M. (2001) Defining the drug-binding site in the human multidrug resistance P-glycoprotein using MTS-verapamil. J. Biol. Chem. 276, 14972-14979.
14. Loo, T. W., and Clarke, D. M. (2001) Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol crosslinkers as molecular rulers. J. Biol. Chem. 276, 36877-36880.
15. Loo, T. W., and Clarke, D. M. (2002) Location of the rhodaminebinding site in the human multidrug resistance P-glycoprotein. J. Biol. Chem. 277, 44332-44338. (Pubitemid 36157868)
16. Pleban, K., Kopp, S., Csaszar, E., Peer, M., Hrebicek, T., Rizzi, A., Ecker, G. F., and Chiba, P. (2005) P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach. Mol. Pharmacol. 67, 365-374. (Pubitemid 40216728)
17. Dey, S., Ramachandra, M., Pastan, I., Gottesman, M. M., and Ambudkar, S. V. (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 94, 10594-10599.
18. Pascaud, C., Garrigos, M., and Orlowski, S. (1998) Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem. J. 333, 351-358. (Pubitemid 28379536)
19. Shapiro, A. B., Fox, K., Lam, P., and Ling, V. (1999) Stimulation of P-glycoprotein-MEDiated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem. 259, 841-850. (Pubitemid 29075514)
20. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2003) Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J. Biol. Chem. 278, 39706-39710. (Pubitemid 37248532)
21. Lugo, M. R., and Sharom, F. J. (2005) Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. Biochemistry 44, 14020-14029. (Pubitemid 41507482)
22. Loo, T. W., and Clarke, D. M. (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J. Biol. Chem. 272, 709-712. (Pubitemid 27034553)
23. Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J. L., Drumm, M. L., Iannuzzi, M. C., Collins, F. S., and Tsui, L.-C. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073. (Pubitemid 19231814)
24. Pedemonte, N., Lukacs, G. L., Du, K., Caci, E., Zegarra-Moran, O., Galietta, L. J., and Verkman, A. S. (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by highthroughput screening. J. Clin. Invest. 115, 2564-2571. (Pubitemid 41266219)
25. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2005) Rescue of ΔF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol. Pharmaceutics 2, 407-413. (Pubitemid 41503681)
26. Van Goor, F., Straley, K. S., Cao, D., Gonzalez, J., Hadida, S., Hazlewood, A., Joubran, J., Knapp, T., Makings, L. R., Miller, M., Neuberger, T., Olson, E., Panchenko, V., Rader, J., Singh, A., Stack, J. H., Tung, R., Grootenhuis, P. D., and Negulescu, P. (2006) Rescue of ΔF508 CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell Mol. Physiol. 290, L1117-L1130. (Pubitemid 43830856)
27. Carlile, G. W., Robert, R., Zhang, D., Teske, K. A., Luo, Y., Hanrahan, J. W., and Thomas, D. Y. (2007) Correctors of protein trafficking defects identified by a novel high-throughput screening assay. ChemBioChem 8, 1012-1020. (Pubitemid 47189285)
28. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2002) Introduction of the most common cystic fibrosis mutation (delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments. J. Biol. Chem. 277, 27585-27588. (Pubitemid 34966699)
29. Chen, E. Y., Bartlett, M. C., Loo, T. W., and Clarke, D.M. (2004) The ΔF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 279, 39620-39627. (Pubitemid 39258229)
30. Serohijos, A. W., Hegedus, T., Aleksandrov, A. A., He, L., Cui, L., Dokholyan, N. V., and Riordan, J. R. (2008) Phenylalanine-508 MEDiates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc. Natl. Acad. Sci. U.S.A. 105, 3256-3261. (Pubitemid 351723540)
31. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2008) Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR). J. Biol. Chem. 283, 28190-28197.
32. Wang, Y., Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2007) Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol. Pharmacol. 71, 751-758. (Pubitemid 46294086)
33. Enquist, K., Fransson, M., Boekel, C., Inger Bengtsson, I., Geiger, K., Lang, L., Pettersson, A., Johansson, S., von Heijne, G., and Nilsson, I. (2009) Membrane-integration characteristics of two ABC transporters, CFTR and P-glycoprotein. J. Mol. Biol. 387, 1153-1164.
34. Skach, W. R., Calayag, M. C., and Lingappa, V. R. (1993) Evidence for an alternate model of human P-glycoprotein structure and biogenesis. J. Biol. Chem. 268, 6903-6908. (Pubitemid 23105571)
35. Skach, W. R., and Lingappa, V. R. (1994) Transmembrane orientation and topogenesis of the third and fourth membrane-spanning regions of human P-glycoprotein (MDR1). Cancer Res. 54, 3202-3209. (Pubitemid 24208929)
36. Zhang, M., Wang, G., Shapiro, A., and Zhang, J. T. (1996) Topological folding and proteolysis profile of P-glycoprotein in membranes of multidrug-resistant cells: implications for the drug-transport mechanism. Biochemistry 35, 9728-9736. (Pubitemid 26302985)
37. Zhang, J. T., Duthie, M., and Ling, V. (1993) Membrane topology of the N-terminal half of the hamster P-glycoprotein molecule. J. Biol. Chem. 268, 15101-15110. (Pubitemid 23206662)
38. Kimchi-Sarfaty, C., Oh, J. M., Kim, I. W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., and Gottesman, M. M. (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315, 525-528. (Pubitemid 46175758)
39. Loo, T. W., and Clarke, D. M. (1998) Superfolding of the partially unfolded core-glycosylated interMEDiate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J. Biol. Chem. 273, 14671-14674. (Pubitemid 28272748)
40. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2006) Insertion of an arginine residue into the transmembrane segments corrects protein misfolding. J. Biol. Chem. 281, 29436-29440. (Pubitemid 44536951)
41. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2008) Arginines in the first transmembrane segment promote maturation of a P-glycoprotein processing mutant by hydrogen bond interactions with tyrosines in transmembrane segment 11. J. Biol. Chem. 283, 24860-24870.
42. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2009) Identification of residues in the drug-translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis. J. Biol. Chem. 284, 24074-24087.
43. Loo, T. W., and Clarke, D. M. (1994) Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. J. Biol. Chem. 269, 7243-7248. (Pubitemid 24217914)
44. Loo, T. W., and Clarke, D. M. (1995) Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drugstimulated ATPase activities. J. Biol. Chem. 270, 21449-21452.
45. Loo, T. W., and Clarke, D.M. (1999) The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates. Biochemistry 38, 5124-5129.
46. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2004) Processing mutations located throughout the human multidrug Resistance P-glycoprotein disrupt interactions between the nucleotide binding domains. J. Biol. Chem. 279, 38395-38401. (Pubitemid 39295989)
47. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2004) Val133 and Cys137 in transmembrane segment 2 are close to residues Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein. J. Biol. Chem. 279, 18232-18238. (Pubitemid 38623236)
48. Chen, C., and Okayama, H. (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7, 2745-2752.
49. Loo, T. W., and Clarke, D. M. (1995) P-glycoprotein. Associations between domains and between domains and molecular chaperones. J. Biol. Chem. 270, 21839-21844.
50. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2005) The dileucine motif at the COOH terminus of human multidrug resistance P-glycoprotein is important for folding but not activity. J. Biol. Chem. 280, 2522-2528. (Pubitemid 40189353)
51. Loo, T. W., and Clarke, D. M. (2000) The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis. J. Biol. Chem. 275, 5253-5256. (Pubitemid 30115151)
52. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2006) Transmembrane segment 7 of human P-glycoprotein forms part of the drugbinding pocket. Biochem. J. 399, 351-359. (Pubitemid 44570297)
53. Loo, T. W., and Clarke, D. M. (1999) The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J. 13, 1724-1732. (Pubitemid 29473334)
54. Chifflet, S., Torriglia, A., Chiesa, R., and Tolosa, S. (1988) A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein: application to lens ATPases. Anal. Biochem. 168, 1-4. (Pubitemid 18088291)
55. Globisch, C., Pajeva, I. K., and Wiese, M. (2008) Identification of putative binding sites of P-glycoprotein based on its homology model. ChemMEDChem 3, 280-295.
56. Dawson, R. J., and Locher, K. P. (2007) Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett. 581, 935-938. (Pubitemid 46282725)
57. DeLano, W. L. (2002) The PyMol Molecular Graphics System, DeLano Scientific, Palo Alto, CA (http://www.pymol.org).
58. Teem, J. L., Berger, H. A., Ostedgaard, L. S., Rich, D. P., Tsui, L. C., and Welsh, M. J. (1993) Identification of revertants for the cystic fibrosis delta F508 mutation using STE6-CFTR chimeras in yeast. Cell 73, 335-346. (Pubitemid 23123311)
59. Teem, J. L., Carson, M. R., and Welsh, M. J. (1996) Mutation of R555 in CFTR-delta F508 enhances function and partially corrects defective processing. Receptors Channels 4, 63-72. (Pubitemid 26144636)
60. DeCarvalho, A. C., Gansheroff, L. J., and Teem, J. L. (2002) Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta F508. J. Biol. Chem. 277, 35896-35905.
61. Chang, X. B., Cui, L., Hou, Y. X., Jensen, T. J., Aleksandrov, A. A., Mengos, A., and Riordan, J. R. (1999) Removal of multiple argininefraMED trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis. Mol. Cell 4, 137-142. (Pubitemid 29386140)
62. Roxo-Rosa, M., Xu, Z., Schmidt, A., Neto, M., Cai, Z., Soares, C. M., Sheppard, D. N., and Amaral, M. D. (2006) Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide- binding domain of CFTR by different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 103, 17891-17896. (Pubitemid 44852256)
63. Pissarra, L. S., Farinha, C. M., Xu, Z., Schmidt, A., Thibodeau, P. H., Cai, Z., Thomas, P. J., Sheppard, D. N., and Amaral, M. D. (2008) Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation. Chem. Biol. 15, 62-69.
64. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2010) The V510D suppressor mutation stabilizes deltaF508-CFTR at the cell surface. Biochemistry 49, 6352-6357.
65. Thibodeau, P. H., Richardson, J. M., III, Wang, W., Millen, L., Watson, J., Mendoza, J. L., Du, K., Fischman, S., Senderowitz, H., Lukacs, G. L., Kirk, K., and Thomas, P. J. (2010) The cystic fibrosiscausing mutation {delta}F508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J. Biol. Chem. 285, 35825-35835.
66. He, L., Aleksandrov, L. A., Cui, L., Jensen, T. J., Nesbitt, K. L., and Riordan, J. R. (2010) Restoration of domain folding and interdomain assembly by second-site suppressors of the deltaF508 mutation in CFTR. FASEB J. 24, 3103-3112.
67. de Planque, M. R., Bonev, B. B., Demmers, J. A., Greathouse, D. V., Koeppe, R. E., II, Separovic, F., Watts, A., and Killian, J. A. (2003) Interfacial anchor properties of tryptophan residues in transmembrane peptides can dominate over hydrophobic matching effects in peptide-lipid interactions. Biochemistry 42, 5341-5348. (Pubitemid 36560430)
68. Loo, T. W., and Clarke, D. M. (1996) Inhibition of oxidative crosslinking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates. J. Biol. Chem. 271, 27482-27487. (Pubitemid 26367309)
69. Zhang, J. T., and Ling, V. (1991) Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. J. Biol. Chem. 266, 18224-18232. (Pubitemid 21908069)
70. Ueda, K., Cardarelli, C., Gottesman, M. M., and Pastan, I. (1987) Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U.S.A. 84, 3004-3008. (Pubitemid 17064766)
71. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2003) Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites. J. Biol. Chem. 278, 50136-50141. (Pubitemid 37548851)
72. Wang, Y., Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2007) Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J. Biol. Chem. 282, 33247-33251. (Pubitemid 350159496)
73. Sheppard, D. N. (2004) CFTR channel pharmacology: novel pore blockers identified by high-throughput screening. J. Gen. Physiol. 124, 109-113. (Pubitemid 39038185)
74. Kalid, O., Mense, M., Fischman, S., Shitrit, A., Bihler, H., Ben-Zeev, E., Schutz, N., Pedemonte, N., Thomas, P. J., Bridges, R. J., Wetmore, D. R., Marantz, Y., and Senderowitz, H. (2010) Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J. Comput.-Aided Mol. Des. 24, 971-991.
75. Seibert, F. S., Jia, Y., Mathews, C. J., Hanrahan, J. W., Riordan, J. R., Loo, T. W., and Clarke, D. M. (1997) Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel. Biochemistry 36, 11966-11974. (Pubitemid 27424126)
76. Seibert, F. S., Linsdell, P., Loo, T. W., Hanrahan, J. W., Clarke, D. M., and Riordan, J. R. (1996) Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity. J. Biol. Chem. 271, 15139-15145. (Pubitemid 26194993)
77. Seibert, F. S., Linsdell, P., Loo, T. W., Hanrahan, J. W., Riordan, J. R., and Clarke, D. M. (1996) Cytoplasmic loop three of cystic fibrosis transmembrane conductance regulator contributes to regulation of chloride channel activity. J. Biol. Chem. 271, 27493-27499. (Pubitemid 26367311)
78. Du, K., Sharma, M., and Lukacs, G. L. (2005) The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat. Struct. Mol. Biol. 12, 17-25. (Pubitemid 40082912)
79. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2009) Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule. Biochemistry 48, 9882-9890.
80. Du, K., and Lukacs, G. L. (2009) Cooperative assembly and misfolding of CFTR domains in vivo. Mol. Biol. Cell 20, 1903-1915.
81. Cui, L., Aleksandrov, L., Chang, X. B., Hou, Y. X., He, L., Hegedus, T., Gentzsch, M., Aleksandrov, A., Balch, W. E., and Riordan, J. R. (2007) Domain interdependence in the biosynthetic assembly of CFTR. J. Mol. Biol. 365, 981-994. (Pubitemid 46014191)
82. Zolnerciks, J. K., Wooding, C., and Linton, K. J. (2007) Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein. FASEB J. 21, 3937-3948. (Pubitemid 350232351)
83. Pagant, S., Halliday, J. J., Kougentakis, C., and Miller, E. A. (2010) Intragenic suppressing mutations correct the folding and intracellular traffic of misfolded mutants of Yor1p, a eukaryotic drug transporter. J. Biol. Chem. 285, 36304-36314.
84. Devine, S. E., Hussain, A., Davide, J. P., and Melera, P. W. (1991) Full length and alternatively spliced pgp1 transcripts in multidrugresistant Chinese hamster lung cells. J. Biol. Chem. 266, 4545-4555. (Pubitemid 21909391)
85. Endicott, J. A., Sarangi, F., and Ling, V. (1991) Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Seq. 2, 89-101.
86. Becker, J. P., Depret, G., Van Bambeke, F., Tulkens, P. M., and Prevost, M. (2009) Molecular models of human P-glycoprotein in two different catalytic states. BMC Struct. Biol. 9, 3.
87. Chang, X. B., Hou, Y. X., Jensen, T. J., and Riordan, J. R. (1994) Mapping of cystic fibrosis transmembrane conductance regulator membrane topology by glycosylation site insertion. J. Biol. Chem. 269, 18572-18575. (Pubitemid 24224095)
88. Kast, C., Canfield, V., Levenson, R., and Gros, P. (1996) Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence. J. Biol. Chem. 271, 9240-9248. (Pubitemid 26137325)
89. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2004) Disulfide crosslinking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane. J. Biol. Chem. 279, 7692-7697. (Pubitemid 38294651)
90. Stenham, D. R., Campbell, J. D., Sansom, M. S., Higgins, C. F., Kerr, I. D., and Linton, K. J. (2003) An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling. FASEB J. 17, 2287-2289. (Pubitemid 39561468)
91. Therien, A. G., Grant, F.E., andDeber, C.M. (2001) Interhelical hydrogen bonds in the CFTR membrane domain. Nat. Struct. Biol. 8, 597-601. (Pubitemid 32613007)
92. Choi, M. Y., Cardarelli, L., Therien, A. G., and Deber, C. M. (2004) Non-native interhelical hydrogen bonds in the cystic fibrosis transmembrane conductance regulator domain modulated by polar mutations. Biochemistry 43, 8077-8083. (Pubitemid 38808262)
93. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2003) Substrateinduced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem. 278, 13603-13606. (Pubitemid 36799891)
94. Loo, T. W., and Clarke, D. M. (2001) Cross-linking of human multidrug resistance P-glycoprotein by the substrate, tris-(2-maleimidoethyl) amine, is altered byATP hydrolysis: evidence for rotation of a transmembrane helix. J. Biol. Chem. 276, 31800-31805.
95. Lukacs, G. L., MohaMED, A., Kartner, N., Chang, X. B., Riordan, J. R., and Grinstein, S. (1994) Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 13, 6076-6086.
96. Chen, E. Y., Bartlett, M. C., and Clarke, D. M. (2000) Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited. Biochemistry 39, 3797-3803. (Pubitemid 30183862)
97. Dawson, R. J., and Locher, K. P. (2006) Structure of a bacterial multidrug ABC transporter. Nature 443, 180-185. (Pubitemid 44387602)
98. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2007) Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments. Biochemistry 46, 9328-9336. (Pubitemid 47255045)
99. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2010) Human P-glycoprotein is active when the two halves are clamped together in the closed conformation.Biochem. Biophys.Res.Commun. 395, 436-440.